NeoGenomics Inc. shares climbed to a 52-week high of $19.78, trading just 0.99% below their peak, as second-quarter results exceeded expectations and an analyst upgraded his outlook on the company.
NeoGenomics reported adjusted earnings per share of $0.05 for the quarter, beating the consensus estimate of $0.03. Revenue came in at $202 million, surpassing the forecast of $196.99 million, and the company raised its full-year 2026 revenue and EBITDA guidance following the results.
Second-quarter organic revenue growth accelerated to 11%, with clinical revenue rising 14%. Non-clinical revenue declined 15%, offsetting some of the upside. The company’s market capitalization stood at approximately $2.54 billion at the time of the filing.
Needham updated its price target on NeoGenomics, raising it from $15.00 to $19.00 while maintaining a Buy rating. The new target sits roughly in line with the stock’s current level, suggesting limited additional upside from that analyst at the moment.
The stock has gained roughly 129% over the past year, with InvestingPro data showing a 133.54% return over the same period. Analysts surveyed by InvestingPro expect the company to be profitable sometime this year, and four analysts have recently revised their earnings estimates upward.
Despite the strong performance, InvestingPro’s fair value analysis suggests the stock may already be overvalued at current levels.
In leadership news, NeoGenomics announced that Executive Vice President, General Counsel and Business Development Alicia Olivo will step down effective September 21, 2026. She will remain with the company through October 2 to assist with the transition, receiving separation payments and benefits per her employment agreement.
